nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—POMC—multiple sclerosis	0.565	1	CbGaD
Loperamide—CYP2D6—Fingolimod—multiple sclerosis	0.0275	0.13	CbGbCtD
Loperamide—ABCB1—Methylprednisolone—multiple sclerosis	0.0188	0.0892	CbGbCtD
Loperamide—CYP3A4—Fingolimod—multiple sclerosis	0.0175	0.083	CbGbCtD
Loperamide—CYP2B6—Dexamethasone—multiple sclerosis	0.0139	0.0658	CbGbCtD
Loperamide—ABCB1—Mitoxantrone—multiple sclerosis	0.0137	0.0651	CbGbCtD
Loperamide—ABCB1—Betamethasone—multiple sclerosis	0.0122	0.058	CbGbCtD
Loperamide—ABCB1—Prednisolone—multiple sclerosis	0.0121	0.0572	CbGbCtD
Loperamide—ABCB1—Prednisone—multiple sclerosis	0.0114	0.0541	CbGbCtD
Loperamide—CYP3A4—Methylprednisolone—multiple sclerosis	0.0113	0.0535	CbGbCtD
Loperamide—CYP2C8—Dexamethasone—multiple sclerosis	0.0105	0.0499	CbGbCtD
Loperamide—CYP3A4—Triamcinolone—multiple sclerosis	0.00855	0.0405	CbGbCtD
Loperamide—CYP3A4—Mitoxantrone—multiple sclerosis	0.00823	0.039	CbGbCtD
Loperamide—CYP3A4—Betamethasone—multiple sclerosis	0.00733	0.0348	CbGbCtD
Loperamide—CYP3A4—Prednisolone—multiple sclerosis	0.00723	0.0343	CbGbCtD
Loperamide—ABCB1—Dexamethasone—multiple sclerosis	0.00712	0.0337	CbGbCtD
Loperamide—CYP3A4—Prednisone—multiple sclerosis	0.00683	0.0324	CbGbCtD
Loperamide—CYP2D6—Dexamethasone—multiple sclerosis	0.00671	0.0318	CbGbCtD
Loperamide—POMC—peripheral nervous system—multiple sclerosis	0.00595	0.0859	CbGeAlD
Loperamide—ABCB1—Methotrexate—multiple sclerosis	0.00572	0.0271	CbGbCtD
Loperamide—POMC—nerve—multiple sclerosis	0.00464	0.067	CbGeAlD
Loperamide—CACNA1A—nerve—multiple sclerosis	0.00443	0.0639	CbGeAlD
Loperamide—CYP3A4—Dexamethasone—multiple sclerosis	0.00426	0.0202	CbGbCtD
Loperamide—Megacolon toxic—Methotrexate—multiple sclerosis	0.00354	0.0641	CcSEcCtD
Loperamide—CALM1—trigeminal nerve—multiple sclerosis	0.00345	0.0499	CbGeAlD
Loperamide—CALM2—pons—multiple sclerosis	0.00244	0.0353	CbGeAlD
Loperamide—CALM1—pons—multiple sclerosis	0.00243	0.0351	CbGeAlD
Loperamide—POMC—brainstem—multiple sclerosis	0.00199	0.0287	CbGeAlD
Loperamide—Altered state of consciousness—Cladribine—multiple sclerosis	0.00195	0.0353	CcSEcCtD
Loperamide—CACNA1A—brainstem—multiple sclerosis	0.0019	0.0274	CbGeAlD
Loperamide—Megacolon—Methotrexate—multiple sclerosis	0.0018	0.0325	CcSEcCtD
Loperamide—OPRM1—nerve—multiple sclerosis	0.00175	0.0252	CbGeAlD
Loperamide—CALM2—pineal body—multiple sclerosis	0.00174	0.0252	CbGeAlD
Loperamide—CALM1—pineal body—multiple sclerosis	0.00174	0.0251	CbGeAlD
Loperamide—CALM2—peripheral nervous system—multiple sclerosis	0.00162	0.0235	CbGeAlD
Loperamide—CALM1—peripheral nervous system—multiple sclerosis	0.00162	0.0234	CbGeAlD
Loperamide—Distention—Prednisone—multiple sclerosis	0.0015	0.0271	CcSEcCtD
Loperamide—POMC—medulla oblongata—multiple sclerosis	0.00139	0.02	CbGeAlD
Loperamide—CACNA1A—medulla oblongata—multiple sclerosis	0.00133	0.0191	CbGeAlD
Loperamide—Ileus—Cladribine—multiple sclerosis	0.00127	0.023	CcSEcCtD
Loperamide—POMC—midbrain—multiple sclerosis	0.00127	0.0183	CbGeAlD
Loperamide—CALM2—nerve—multiple sclerosis	0.00127	0.0183	CbGeAlD
Loperamide—CALM1—nerve—multiple sclerosis	0.00126	0.0182	CbGeAlD
Loperamide—POMC—spinal cord—multiple sclerosis	0.00124	0.0179	CbGeAlD
Loperamide—Epigastric pain—Mitoxantrone—multiple sclerosis	0.00123	0.0222	CcSEcCtD
Loperamide—POMC—nervous system—multiple sclerosis	0.00104	0.0151	CbGeAlD
Loperamide—POMC—central nervous system—multiple sclerosis	0.001	0.0145	CbGeAlD
Loperamide—CACNA1A—nervous system—multiple sclerosis	0.000996	0.0144	CbGeAlD
Loperamide—POMC—cerebellum—multiple sclerosis	0.000981	0.0142	CbGeAlD
Loperamide—CACNA1A—central nervous system—multiple sclerosis	0.000959	0.0138	CbGeAlD
Loperamide—CACNA1A—cerebellum—multiple sclerosis	0.000937	0.0135	CbGeAlD
Loperamide—Depressed level of consciousness—Cladribine—multiple sclerosis	0.00087	0.0157	CcSEcCtD
Loperamide—POMC—brain—multiple sclerosis	0.000797	0.0115	CbGeAlD
Loperamide—CACNA1A—brain—multiple sclerosis	0.000761	0.011	CbGeAlD
Loperamide—OPRM1—brainstem—multiple sclerosis	0.000749	0.0108	CbGeAlD
Loperamide—CALM3—retina—multiple sclerosis	0.000668	0.00965	CbGeAlD
Loperamide—Toxic epidermal necrolysis—Cladribine—multiple sclerosis	0.000589	0.0107	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.000588	0.0106	CcSEcCtD
Loperamide—OPRD1—nervous system—multiple sclerosis	0.000576	0.00831	CbGeAlD
Loperamide—Nervous system disorder—Fingolimod—multiple sclerosis	0.000556	0.0101	CcSEcCtD
Loperamide—OPRD1—central nervous system—multiple sclerosis	0.000554	0.008	CbGeAlD
Loperamide—OPRK1—nervous system—multiple sclerosis	0.000552	0.00797	CbGeAlD
Loperamide—Skin disorder—Fingolimod—multiple sclerosis	0.000551	0.00997	CcSEcCtD
Loperamide—CALM2—brainstem—multiple sclerosis	0.000544	0.00785	CbGeAlD
Loperamide—CALM1—brainstem—multiple sclerosis	0.000541	0.00782	CbGeAlD
Loperamide—OPRK1—central nervous system—multiple sclerosis	0.000531	0.00767	CbGeAlD
Loperamide—CALM2—retina—multiple sclerosis	0.000525	0.00757	CbGeAlD
Loperamide—CALM1—retina—multiple sclerosis	0.000522	0.00754	CbGeAlD
Loperamide—OPRK1—cerebellum—multiple sclerosis	0.000519	0.0075	CbGeAlD
Loperamide—Stevens-Johnson syndrome—Cladribine—multiple sclerosis	0.0005	0.00904	CcSEcCtD
Loperamide—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00049	0.00886	CcSEcCtD
Loperamide—Fatigue—Fingolimod—multiple sclerosis	0.000489	0.00885	CcSEcCtD
Loperamide—CALM3—medulla oblongata—multiple sclerosis	0.000483	0.00697	CbGeAlD
Loperamide—Toxic epidermal necrolysis—Azathioprine—multiple sclerosis	0.000479	0.00866	CcSEcCtD
Loperamide—OPRM1—midbrain—multiple sclerosis	0.000477	0.00689	CbGeAlD
Loperamide—OPRM1—spinal cord—multiple sclerosis	0.000466	0.00673	CbGeAlD
Loperamide—Urinary tract disorder—Cladribine—multiple sclerosis	0.000447	0.00808	CcSEcCtD
Loperamide—Anaphylactoid reaction—Mitoxantrone—multiple sclerosis	0.000444	0.00804	CcSEcCtD
Loperamide—Urethral disorder—Cladribine—multiple sclerosis	0.000444	0.00802	CcSEcCtD
Loperamide—CALM3—midbrain—multiple sclerosis	0.000441	0.00637	CbGeAlD
Loperamide—OPRD1—brain—multiple sclerosis	0.00044	0.00635	CbGeAlD
Loperamide—CALM3—spinal cord—multiple sclerosis	0.00043	0.00622	CbGeAlD
Loperamide—Erythema multiforme—Cladribine—multiple sclerosis	0.000428	0.00774	CcSEcCtD
Loperamide—OPRK1—brain—multiple sclerosis	0.000422	0.00609	CbGeAlD
Loperamide—Immune system disorder—Cladribine—multiple sclerosis	0.000409	0.00739	CcSEcCtD
Loperamide—Asthenia—Fingolimod—multiple sclerosis	0.000407	0.00736	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Azathioprine—multiple sclerosis	0.000406	0.00735	CcSEcCtD
Loperamide—Pruritus—Fingolimod—multiple sclerosis	0.000401	0.00726	CcSEcCtD
Loperamide—Abdominal pain upper—Mitoxantrone—multiple sclerosis	0.000393	0.0071	CcSEcCtD
Loperamide—OPRM1—nervous system—multiple sclerosis	0.000393	0.00567	CbGeAlD
Loperamide—Flatulence—Cladribine—multiple sclerosis	0.000388	0.00702	CcSEcCtD
Loperamide—Diarrhoea—Fingolimod—multiple sclerosis	0.000388	0.00702	CcSEcCtD
Loperamide—CALM2—medulla oblongata—multiple sclerosis	0.000379	0.00547	CbGeAlD
Loperamide—OPRM1—central nervous system—multiple sclerosis	0.000378	0.00546	CbGeAlD
Loperamide—CALM1—medulla oblongata—multiple sclerosis	0.000377	0.00545	CbGeAlD
Loperamide—Dizziness—Fingolimod—multiple sclerosis	0.000375	0.00678	CcSEcCtD
Loperamide—Dermatitis bullous—Prednisolone—multiple sclerosis	0.000369	0.00668	CcSEcCtD
Loperamide—Anaphylactoid reaction—Prednisolone—multiple sclerosis	0.000365	0.00659	CcSEcCtD
Loperamide—Headache—Fingolimod—multiple sclerosis	0.000355	0.00643	CcSEcCtD
Loperamide—Erythema multiforme—Azathioprine—multiple sclerosis	0.000348	0.00629	CcSEcCtD
Loperamide—CALM2—midbrain—multiple sclerosis	0.000347	0.005	CbGeAlD
Loperamide—CALM1—midbrain—multiple sclerosis	0.000345	0.00498	CbGeAlD
Loperamide—CALM3—cerebellum—multiple sclerosis	0.000341	0.00493	CbGeAlD
Loperamide—Dermatitis bullous—Triamcinolone—multiple sclerosis	0.00034	0.00614	CcSEcCtD
Loperamide—CALM2—spinal cord—multiple sclerosis	0.000338	0.00488	CbGeAlD
Loperamide—CALM1—spinal cord—multiple sclerosis	0.000337	0.00486	CbGeAlD
Loperamide—Anaphylactoid reaction—Triamcinolone—multiple sclerosis	0.000335	0.00606	CcSEcCtD
Loperamide—Anaphylactoid reaction—Methylprednisolone—multiple sclerosis	0.000335	0.00605	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000333	0.00602	CcSEcCtD
Loperamide—Immune system disorder—Azathioprine—multiple sclerosis	0.000332	0.00601	CcSEcCtD
Loperamide—Discomfort—Cladribine—multiple sclerosis	0.000331	0.00599	CcSEcCtD
Loperamide—Drowsiness—Mitoxantrone—multiple sclerosis	0.000331	0.00599	CcSEcCtD
Loperamide—Nervous system disorder—Cladribine—multiple sclerosis	0.000315	0.0057	CcSEcCtD
Loperamide—Skin disorder—Cladribine—multiple sclerosis	0.000312	0.00565	CcSEcCtD
Loperamide—Dermatitis bullous—Dexamethasone—multiple sclerosis	0.000308	0.00557	CcSEcCtD
Loperamide—Dermatitis bullous—Betamethasone—multiple sclerosis	0.000308	0.00557	CcSEcCtD
Loperamide—Abdominal distension—Prednisolone—multiple sclerosis	0.000307	0.00555	CcSEcCtD
Loperamide—Anaphylactoid reaction—Betamethasone—multiple sclerosis	0.000304	0.0055	CcSEcCtD
Loperamide—Anaphylactoid reaction—Dexamethasone—multiple sclerosis	0.000304	0.0055	CcSEcCtD
Loperamide—CYP2D6—brainstem—multiple sclerosis	0.0003	0.00434	CbGeAlD
Loperamide—OPRM1—brain—multiple sclerosis	0.0003	0.00433	CbGeAlD
Loperamide—Somnolence—Cladribine—multiple sclerosis	0.000286	0.00517	CcSEcCtD
Loperamide—Depressed level of consciousness—Methotrexate—multiple sclerosis	0.000285	0.00515	CcSEcCtD
Loperamide—CALM2—nervous system—multiple sclerosis	0.000285	0.00411	CbGeAlD
Loperamide—CALM1—nervous system—multiple sclerosis	0.000284	0.00409	CbGeAlD
Loperamide—Abdominal distension—Triamcinolone—multiple sclerosis	0.000282	0.00511	CcSEcCtD
Loperamide—Abdominal distension—Methylprednisolone—multiple sclerosis	0.000282	0.00509	CcSEcCtD
Loperamide—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000278	0.00502	CcSEcCtD
Loperamide—Fatigue—Cladribine—multiple sclerosis	0.000277	0.00501	CcSEcCtD
Loperamide—CALM3—brain—multiple sclerosis	0.000277	0.004	CbGeAlD
Loperamide—Constipation—Cladribine—multiple sclerosis	0.000275	0.00497	CcSEcCtD
Loperamide—CALM2—central nervous system—multiple sclerosis	0.000274	0.00396	CbGeAlD
Loperamide—CALM1—central nervous system—multiple sclerosis	0.000273	0.00394	CbGeAlD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000271	0.0049	CcSEcCtD
Loperamide—Discomfort—Azathioprine—multiple sclerosis	0.00027	0.00487	CcSEcCtD
Loperamide—CALM2—cerebellum—multiple sclerosis	0.000268	0.00387	CbGeAlD
Loperamide—CALM1—cerebellum—multiple sclerosis	0.000267	0.00385	CbGeAlD
Loperamide—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000263	0.00476	CcSEcCtD
Loperamide—Urticaria—Cladribine—multiple sclerosis	0.000255	0.00462	CcSEcCtD
Loperamide—Abdominal pain—Cladribine—multiple sclerosis	0.000254	0.0046	CcSEcCtD
Loperamide—Skin disorder—Azathioprine—multiple sclerosis	0.000254	0.00459	CcSEcCtD
Loperamide—Hypersensitivity—Cladribine—multiple sclerosis	0.000237	0.00428	CcSEcCtD
Loperamide—Asthenia—Cladribine—multiple sclerosis	0.000231	0.00417	CcSEcCtD
Loperamide—Pruritus—Cladribine—multiple sclerosis	0.000228	0.00411	CcSEcCtD
Loperamide—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000226	0.00408	CcSEcCtD
Loperamide—Abdominal distension—Prednisone—multiple sclerosis	0.000223	0.00403	CcSEcCtD
Loperamide—Anaphylactoid reaction—Methotrexate—multiple sclerosis	0.000221	0.004	CcSEcCtD
Loperamide—Diarrhoea—Cladribine—multiple sclerosis	0.00022	0.00398	CcSEcCtD
Loperamide—Discomfort—Mitoxantrone—multiple sclerosis	0.000218	0.00394	CcSEcCtD
Loperamide—CALM2—brain—multiple sclerosis	0.000218	0.00314	CbGeAlD
Loperamide—CALM1—brain—multiple sclerosis	0.000217	0.00313	CbGeAlD
Loperamide—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000214	0.00387	CcSEcCtD
Loperamide—Dizziness—Cladribine—multiple sclerosis	0.000213	0.00385	CcSEcCtD
Loperamide—CYP2B6—nervous system—multiple sclerosis	0.000212	0.00306	CbGeAlD
Loperamide—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000211	0.00382	CcSEcCtD
Loperamide—ABCB1—retina—multiple sclerosis	0.000208	0.00301	CbGeAlD
Loperamide—Abdominal pain—Azathioprine—multiple sclerosis	0.000207	0.00374	CcSEcCtD
Loperamide—Skin disorder—Mitoxantrone—multiple sclerosis	0.000205	0.00371	CcSEcCtD
Loperamide—Vomiting—Cladribine—multiple sclerosis	0.000204	0.0037	CcSEcCtD
Loperamide—CYP2B6—central nervous system—multiple sclerosis	0.000204	0.00294	CbGeAlD
Loperamide—Rash—Cladribine—multiple sclerosis	0.000203	0.00367	CcSEcCtD
Loperamide—Dermatitis—Cladribine—multiple sclerosis	0.000203	0.00366	CcSEcCtD
Loperamide—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000202	0.00366	CcSEcCtD
Loperamide—Headache—Cladribine—multiple sclerosis	0.000201	0.00364	CcSEcCtD
Loperamide—Angioedema—Prednisolone—multiple sclerosis	0.000194	0.00351	CcSEcCtD
Loperamide—Toxic epidermal necrolysis—Methotrexate—multiple sclerosis	0.000193	0.00349	CcSEcCtD
Loperamide—Hypersensitivity—Azathioprine—multiple sclerosis	0.000193	0.00348	CcSEcCtD
Loperamide—Nausea—Cladribine—multiple sclerosis	0.000191	0.00345	CcSEcCtD
Loperamide—Somnolence—Mitoxantrone—multiple sclerosis	0.000188	0.0034	CcSEcCtD
Loperamide—Loss of consciousness—Prednisolone—multiple sclerosis	0.000187	0.00338	CcSEcCtD
Loperamide—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000186	0.00336	CcSEcCtD
Loperamide—Fatigue—Mitoxantrone—multiple sclerosis	0.000182	0.0033	CcSEcCtD
Loperamide—Constipation—Mitoxantrone—multiple sclerosis	0.000181	0.00327	CcSEcCtD
Loperamide—CYP2C8—brain—multiple sclerosis	0.00018	0.00261	CbGeAlD
Loperamide—Diarrhoea—Azathioprine—multiple sclerosis	0.000179	0.00324	CcSEcCtD
Loperamide—Discomfort—Prednisolone—multiple sclerosis	0.000179	0.00323	CcSEcCtD
Loperamide—Angioedema—Triamcinolone—multiple sclerosis	0.000179	0.00323	CcSEcCtD
Loperamide—Angioedema—Methylprednisolone—multiple sclerosis	0.000178	0.00322	CcSEcCtD
Loperamide—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000173	0.00314	CcSEcCtD
Loperamide—Dizziness—Azathioprine—multiple sclerosis	0.000173	0.00313	CcSEcCtD
Loperamide—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000173	0.00313	CcSEcCtD
Loperamide—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000172	0.00311	CcSEcCtD
Loperamide—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000171	0.0031	CcSEcCtD
Loperamide—Urticaria—Mitoxantrone—multiple sclerosis	0.000168	0.00304	CcSEcCtD
Loperamide—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000167	0.00302	CcSEcCtD
Loperamide—Vomiting—Azathioprine—multiple sclerosis	0.000166	0.00301	CcSEcCtD
Loperamide—Drowsiness—Methotrexate—multiple sclerosis	0.000165	0.00299	CcSEcCtD
Loperamide—Rash—Azathioprine—multiple sclerosis	0.000165	0.00298	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000165	0.00298	CcSEcCtD
Loperamide—Dermatitis—Azathioprine—multiple sclerosis	0.000165	0.00298	CcSEcCtD
Loperamide—Discomfort—Triamcinolone—multiple sclerosis	0.000164	0.00297	CcSEcCtD
Loperamide—Discomfort—Methylprednisolone—multiple sclerosis	0.000164	0.00297	CcSEcCtD
Loperamide—Headache—Azathioprine—multiple sclerosis	0.000164	0.00296	CcSEcCtD
Loperamide—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000164	0.00296	CcSEcCtD
Loperamide—Dry mouth—Triamcinolone—multiple sclerosis	0.000163	0.00294	CcSEcCtD
Loperamide—Angioedema—Dexamethasone—multiple sclerosis	0.000162	0.00293	CcSEcCtD
Loperamide—Angioedema—Betamethasone—multiple sclerosis	0.000162	0.00293	CcSEcCtD
Loperamide—CYP2B6—brain—multiple sclerosis	0.000162	0.00234	CbGeAlD
Loperamide—Immune system disorder—Prednisone—multiple sclerosis	0.00016	0.0029	CcSEcCtD
Loperamide—CYP3A4—nervous system—multiple sclerosis	0.00016	0.00231	CbGeAlD
Loperamide—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000159	0.00288	CcSEcCtD
Loperamide—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000159	0.00288	CcSEcCtD
Loperamide—CYP2D6—nervous system—multiple sclerosis	0.000157	0.00227	CbGeAlD
Loperamide—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000156	0.00282	CcSEcCtD
Loperamide—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000156	0.00282	CcSEcCtD
Loperamide—Loss of consciousness—Betamethasone—multiple sclerosis	0.000156	0.00282	CcSEcCtD
Loperamide—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000156	0.00282	CcSEcCtD
Loperamide—Nausea—Azathioprine—multiple sclerosis	0.000155	0.00281	CcSEcCtD
Loperamide—Skin disorder—Methylprednisolone—multiple sclerosis	0.000155	0.0028	CcSEcCtD
Loperamide—CYP3A4—central nervous system—multiple sclerosis	0.000154	0.00222	CbGeAlD
Loperamide—Asthenia—Mitoxantrone—multiple sclerosis	0.000152	0.00274	CcSEcCtD
Loperamide—CYP2D6—central nervous system—multiple sclerosis	0.000152	0.00219	CbGeAlD
Loperamide—ABCB1—medulla oblongata—multiple sclerosis	0.000151	0.00218	CbGeAlD
Loperamide—Discomfort—Betamethasone—multiple sclerosis	0.000149	0.0027	CcSEcCtD
Loperamide—Discomfort—Dexamethasone—multiple sclerosis	0.000149	0.0027	CcSEcCtD
Loperamide—CYP2D6—cerebellum—multiple sclerosis	0.000148	0.00214	CbGeAlD
Loperamide—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000146	0.00265	CcSEcCtD
Loperamide—Urethral disorder—Methotrexate—multiple sclerosis	0.000145	0.00263	CcSEcCtD
Loperamide—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000145	0.00262	CcSEcCtD
Loperamide—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000145	0.00262	CcSEcCtD
Loperamide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000145	0.00262	CcSEcCtD
Loperamide—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000142	0.00257	CcSEcCtD
Loperamide—Nervous system disorder—Betamethasone—multiple sclerosis	0.000142	0.00257	CcSEcCtD
Loperamide—Angioedema—Prednisone—multiple sclerosis	0.000141	0.00255	CcSEcCtD
Loperamide—Dyspepsia—Triamcinolone—multiple sclerosis	0.00014	0.00254	CcSEcCtD
Loperamide—Erythema multiforme—Methotrexate—multiple sclerosis	0.00014	0.00253	CcSEcCtD
Loperamide—Dyspepsia—Methylprednisolone—multiple sclerosis	0.00014	0.00253	CcSEcCtD
Loperamide—Urticaria—Prednisolone—multiple sclerosis	0.000138	0.00249	CcSEcCtD
Loperamide—ABCB1—midbrain—multiple sclerosis	0.000138	0.00199	CbGeAlD
Loperamide—Fatigue—Triamcinolone—multiple sclerosis	0.000138	0.00249	CcSEcCtD
Loperamide—Fatigue—Methylprednisolone—multiple sclerosis	0.000137	0.00248	CcSEcCtD
Loperamide—Loss of consciousness—Prednisone—multiple sclerosis	0.000136	0.00245	CcSEcCtD
Loperamide—Vomiting—Mitoxantrone—multiple sclerosis	0.000134	0.00243	CcSEcCtD
Loperamide—ABCB1—spinal cord—multiple sclerosis	0.000134	0.00194	CbGeAlD
Loperamide—Immune system disorder—Methotrexate—multiple sclerosis	0.000134	0.00242	CcSEcCtD
Loperamide—Rash—Mitoxantrone—multiple sclerosis	0.000133	0.00241	CcSEcCtD
Loperamide—Dermatitis—Mitoxantrone—multiple sclerosis	0.000133	0.00241	CcSEcCtD
Loperamide—Headache—Mitoxantrone—multiple sclerosis	0.000132	0.00239	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000131	0.00236	CcSEcCtD
Loperamide—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.00013	0.00235	CcSEcCtD
Loperamide—Discomfort—Prednisone—multiple sclerosis	0.00013	0.00235	CcSEcCtD
Loperamide—Hypersensitivity—Prednisolone—multiple sclerosis	0.000128	0.00231	CcSEcCtD
Loperamide—Dyspepsia—Dexamethasone—multiple sclerosis	0.000127	0.0023	CcSEcCtD
Loperamide—Dyspepsia—Betamethasone—multiple sclerosis	0.000127	0.0023	CcSEcCtD
Loperamide—Urticaria—Triamcinolone—multiple sclerosis	0.000127	0.00229	CcSEcCtD
Loperamide—Urticaria—Methylprednisolone—multiple sclerosis	0.000126	0.00229	CcSEcCtD
Loperamide—Anaphylactic shock—Prednisone—multiple sclerosis	0.000126	0.00228	CcSEcCtD
Loperamide—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000126	0.00227	CcSEcCtD
Loperamide—Nausea—Mitoxantrone—multiple sclerosis	0.000126	0.00227	CcSEcCtD
Loperamide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000125	0.00226	CcSEcCtD
Loperamide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000125	0.00226	CcSEcCtD
Loperamide—Fatigue—Dexamethasone—multiple sclerosis	0.000125	0.00226	CcSEcCtD
Loperamide—Fatigue—Betamethasone—multiple sclerosis	0.000125	0.00226	CcSEcCtD
Loperamide—Nervous system disorder—Prednisone—multiple sclerosis	0.000124	0.00223	CcSEcCtD
Loperamide—Skin disorder—Prednisone—multiple sclerosis	0.000122	0.00221	CcSEcCtD
Loperamide—CYP2D6—brain—multiple sclerosis	0.00012	0.00174	CbGeAlD
Loperamide—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000118	0.00214	CcSEcCtD
Loperamide—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000118	0.00214	CcSEcCtD
Loperamide—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000118	0.00212	CcSEcCtD
Loperamide—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000117	0.00212	CcSEcCtD
Loperamide—Urticaria—Betamethasone—multiple sclerosis	0.000115	0.00208	CcSEcCtD
Loperamide—Urticaria—Dexamethasone—multiple sclerosis	0.000115	0.00208	CcSEcCtD
Loperamide—Dizziness—Prednisolone—multiple sclerosis	0.000115	0.00207	CcSEcCtD
Loperamide—Asthenia—Triamcinolone—multiple sclerosis	0.000114	0.00207	CcSEcCtD
Loperamide—Abdominal pain—Dexamethasone—multiple sclerosis	0.000114	0.00207	CcSEcCtD
Loperamide—Abdominal pain—Betamethasone—multiple sclerosis	0.000114	0.00207	CcSEcCtD
Loperamide—Asthenia—Methylprednisolone—multiple sclerosis	0.000114	0.00206	CcSEcCtD
Loperamide—ABCB1—nervous system—multiple sclerosis	0.000113	0.00163	CbGeAlD
Loperamide—Pruritus—Triamcinolone—multiple sclerosis	0.000113	0.00204	CcSEcCtD
Loperamide—Pruritus—Methylprednisolone—multiple sclerosis	0.000113	0.00204	CcSEcCtD
Loperamide—Dyspepsia—Prednisone—multiple sclerosis	0.000111	0.00201	CcSEcCtD
Loperamide—Rash—Prednisolone—multiple sclerosis	0.000109	0.00198	CcSEcCtD
Loperamide—Dermatitis—Prednisolone—multiple sclerosis	0.000109	0.00198	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000109	0.00197	CcSEcCtD
Loperamide—ABCB1—central nervous system—multiple sclerosis	0.000109	0.00157	CbGeAlD
Loperamide—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000109	0.00197	CcSEcCtD
Loperamide—Fatigue—Prednisone—multiple sclerosis	0.000109	0.00196	CcSEcCtD
Loperamide—Headache—Prednisolone—multiple sclerosis	0.000109	0.00196	CcSEcCtD
Loperamide—Discomfort—Methotrexate—multiple sclerosis	0.000109	0.00196	CcSEcCtD
Loperamide—Constipation—Prednisone—multiple sclerosis	0.000108	0.00195	CcSEcCtD
Loperamide—ABCB1—cerebellum—multiple sclerosis	0.000107	0.00154	CbGeAlD
Loperamide—Dizziness—Triamcinolone—multiple sclerosis	0.000105	0.00191	CcSEcCtD
Loperamide—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000105	0.0019	CcSEcCtD
Loperamide—Dizziness—Methylprednisolone—multiple sclerosis	0.000105	0.0019	CcSEcCtD
Loperamide—Asthenia—Dexamethasone—multiple sclerosis	0.000104	0.00188	CcSEcCtD
Loperamide—Asthenia—Betamethasone—multiple sclerosis	0.000104	0.00188	CcSEcCtD
Loperamide—Nervous system disorder—Methotrexate—multiple sclerosis	0.000103	0.00187	CcSEcCtD
Loperamide—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000103	0.00186	CcSEcCtD
Loperamide—Nausea—Prednisolone—multiple sclerosis	0.000103	0.00186	CcSEcCtD
Loperamide—Pruritus—Dexamethasone—multiple sclerosis	0.000102	0.00185	CcSEcCtD
Loperamide—Pruritus—Betamethasone—multiple sclerosis	0.000102	0.00185	CcSEcCtD
Loperamide—Skin disorder—Methotrexate—multiple sclerosis	0.000102	0.00185	CcSEcCtD
Loperamide—Vomiting—Triamcinolone—multiple sclerosis	0.000101	0.00183	CcSEcCtD
Loperamide—Vomiting—Methylprednisolone—multiple sclerosis	0.000101	0.00183	CcSEcCtD
Loperamide—Rash—Triamcinolone—multiple sclerosis	0.000101	0.00182	CcSEcCtD
Loperamide—Dermatitis—Triamcinolone—multiple sclerosis	0.0001	0.00182	CcSEcCtD
Loperamide—Rash—Methylprednisolone—multiple sclerosis	0.0001	0.00181	CcSEcCtD
Loperamide—Dermatitis—Methylprednisolone—multiple sclerosis	0.0001	0.00181	CcSEcCtD
Loperamide—Urticaria—Prednisone—multiple sclerosis	0.0001	0.00181	CcSEcCtD
Loperamide—Headache—Triamcinolone—multiple sclerosis	9.99e-05	0.00181	CcSEcCtD
Loperamide—Headache—Methylprednisolone—multiple sclerosis	9.97e-05	0.0018	CcSEcCtD
Loperamide—Abdominal pain—Prednisone—multiple sclerosis	9.96e-05	0.0018	CcSEcCtD
Loperamide—Diarrhoea—Betamethasone—multiple sclerosis	9.9e-05	0.00179	CcSEcCtD
Loperamide—Diarrhoea—Dexamethasone—multiple sclerosis	9.9e-05	0.00179	CcSEcCtD
Loperamide—Dizziness—Dexamethasone—multiple sclerosis	9.57e-05	0.00173	CcSEcCtD
Loperamide—Dizziness—Betamethasone—multiple sclerosis	9.57e-05	0.00173	CcSEcCtD
Loperamide—Nausea—Triamcinolone—multiple sclerosis	9.47e-05	0.00171	CcSEcCtD
Loperamide—Nausea—Methylprednisolone—multiple sclerosis	9.45e-05	0.00171	CcSEcCtD
Loperamide—Somnolence—Methotrexate—multiple sclerosis	9.36e-05	0.00169	CcSEcCtD
Loperamide—Hypersensitivity—Prednisone—multiple sclerosis	9.28e-05	0.00168	CcSEcCtD
Loperamide—Dyspepsia—Methotrexate—multiple sclerosis	9.27e-05	0.00168	CcSEcCtD
Loperamide—Vomiting—Betamethasone—multiple sclerosis	9.2e-05	0.00166	CcSEcCtD
Loperamide—Vomiting—Dexamethasone—multiple sclerosis	9.2e-05	0.00166	CcSEcCtD
Loperamide—Rash—Dexamethasone—multiple sclerosis	9.12e-05	0.00165	CcSEcCtD
Loperamide—Rash—Betamethasone—multiple sclerosis	9.12e-05	0.00165	CcSEcCtD
Loperamide—Dermatitis—Betamethasone—multiple sclerosis	9.12e-05	0.00165	CcSEcCtD
Loperamide—Dermatitis—Dexamethasone—multiple sclerosis	9.12e-05	0.00165	CcSEcCtD
Loperamide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	9.09e-05	0.00164	CcSEcCtD
Loperamide—Fatigue—Methotrexate—multiple sclerosis	9.08e-05	0.00164	CcSEcCtD
Loperamide—Headache—Betamethasone—multiple sclerosis	9.07e-05	0.00164	CcSEcCtD
Loperamide—Headache—Dexamethasone—multiple sclerosis	9.07e-05	0.00164	CcSEcCtD
Loperamide—Asthenia—Prednisone—multiple sclerosis	9.04e-05	0.00164	CcSEcCtD
Loperamide—Pruritus—Prednisone—multiple sclerosis	8.92e-05	0.00161	CcSEcCtD
Loperamide—ABCB1—brain—multiple sclerosis	8.65e-05	0.00125	CbGeAlD
Loperamide—Diarrhoea—Prednisone—multiple sclerosis	8.62e-05	0.00156	CcSEcCtD
Loperamide—Gastrointestinal pain—Methotrexate—multiple sclerosis	8.61e-05	0.00156	CcSEcCtD
Loperamide—Nausea—Dexamethasone—multiple sclerosis	8.6e-05	0.00155	CcSEcCtD
Loperamide—Nausea—Betamethasone—multiple sclerosis	8.6e-05	0.00155	CcSEcCtD
Loperamide—Urticaria—Methotrexate—multiple sclerosis	8.37e-05	0.00151	CcSEcCtD
Loperamide—Dizziness—Prednisone—multiple sclerosis	8.33e-05	0.00151	CcSEcCtD
Loperamide—Abdominal pain—Methotrexate—multiple sclerosis	8.33e-05	0.00151	CcSEcCtD
Loperamide—Vomiting—Prednisone—multiple sclerosis	8.01e-05	0.00145	CcSEcCtD
Loperamide—Rash—Prednisone—multiple sclerosis	7.95e-05	0.00144	CcSEcCtD
Loperamide—Dermatitis—Prednisone—multiple sclerosis	7.94e-05	0.00144	CcSEcCtD
Loperamide—Headache—Prednisone—multiple sclerosis	7.89e-05	0.00143	CcSEcCtD
Loperamide—Hypersensitivity—Methotrexate—multiple sclerosis	7.76e-05	0.0014	CcSEcCtD
Loperamide—Asthenia—Methotrexate—multiple sclerosis	7.56e-05	0.00137	CcSEcCtD
Loperamide—Nausea—Prednisone—multiple sclerosis	7.49e-05	0.00135	CcSEcCtD
Loperamide—Pruritus—Methotrexate—multiple sclerosis	7.45e-05	0.00135	CcSEcCtD
Loperamide—Diarrhoea—Methotrexate—multiple sclerosis	7.21e-05	0.0013	CcSEcCtD
Loperamide—Dizziness—Methotrexate—multiple sclerosis	6.96e-05	0.00126	CcSEcCtD
Loperamide—Vomiting—Methotrexate—multiple sclerosis	6.7e-05	0.00121	CcSEcCtD
Loperamide—Rash—Methotrexate—multiple sclerosis	6.64e-05	0.0012	CcSEcCtD
Loperamide—Dermatitis—Methotrexate—multiple sclerosis	6.63e-05	0.0012	CcSEcCtD
Loperamide—Headache—Methotrexate—multiple sclerosis	6.6e-05	0.00119	CcSEcCtD
Loperamide—Nausea—Methotrexate—multiple sclerosis	6.26e-05	0.00113	CcSEcCtD
Loperamide—CALM3—Signaling Pathways—CXCR3—multiple sclerosis	6.91e-06	6.92e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL2RA—multiple sclerosis	6.89e-06	6.91e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—IL6—multiple sclerosis	6.85e-06	6.86e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CD28—multiple sclerosis	6.84e-06	6.86e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—IL2—multiple sclerosis	6.84e-06	6.85e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-B—multiple sclerosis	6.81e-06	6.83e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-B—multiple sclerosis	6.81e-06	6.83e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—PGR—multiple sclerosis	6.81e-06	6.83e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—PGR—multiple sclerosis	6.81e-06	6.83e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—BCHE—multiple sclerosis	6.81e-06	6.82e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CD80—multiple sclerosis	6.81e-06	6.82e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CD86—multiple sclerosis	6.74e-06	6.76e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CD86—multiple sclerosis	6.74e-06	6.76e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCR2—multiple sclerosis	6.72e-06	6.73e-05	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD4—multiple sclerosis	6.71e-06	6.72e-05	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CD4—multiple sclerosis	6.71e-06	6.72e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CXCR3—multiple sclerosis	6.68e-06	6.69e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CXCR3—multiple sclerosis	6.68e-06	6.69e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—IL6—multiple sclerosis	6.62e-06	6.64e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—IL6—multiple sclerosis	6.62e-06	6.64e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CD28—multiple sclerosis	6.62e-06	6.63e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CD28—multiple sclerosis	6.62e-06	6.63e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL2RA—multiple sclerosis	6.6e-06	6.61e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TYK2—multiple sclerosis	6.55e-06	6.57e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-A—multiple sclerosis	6.53e-06	6.54e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCR2—multiple sclerosis	6.5e-06	6.51e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCR2—multiple sclerosis	6.5e-06	6.51e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—POMC—multiple sclerosis	6.47e-06	6.48e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL2RA—multiple sclerosis	6.38e-06	6.4e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL2RA—multiple sclerosis	6.38e-06	6.4e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—RRM1—multiple sclerosis	6.37e-06	6.38e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—APOE—multiple sclerosis	6.36e-06	6.38e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CCL2—multiple sclerosis	6.33e-06	6.34e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-A—multiple sclerosis	6.31e-06	6.32e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-A—multiple sclerosis	6.31e-06	6.32e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CNR1—multiple sclerosis	6.2e-06	6.21e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—MAPK1—multiple sclerosis	6.19e-06	6.2e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CCR5—multiple sclerosis	6.18e-06	6.19e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—HLA-A—multiple sclerosis	6.02e-06	6.04e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CNR1—multiple sclerosis	6e-06	6.01e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CNR1—multiple sclerosis	6e-06	6.01e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CCR5—multiple sclerosis	5.98e-06	5.99e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CCR5—multiple sclerosis	5.98e-06	5.99e-05	CbGpPWpGaD
Loperamide—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	5.97e-06	5.98e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—TLR4—multiple sclerosis	5.97e-06	5.98e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-DRB1—multiple sclerosis	5.96e-06	5.97e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—BCHE—multiple sclerosis	5.93e-06	5.95e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—HLA-A—multiple sclerosis	5.83e-06	5.84e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—HLA-A—multiple sclerosis	5.83e-06	5.84e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—TLR4—multiple sclerosis	5.77e-06	5.78e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—TLR4—multiple sclerosis	5.77e-06	5.78e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-DRB1—multiple sclerosis	5.77e-06	5.78e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-DRB1—multiple sclerosis	5.77e-06	5.78e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—TGFB1—multiple sclerosis	5.76e-06	5.77e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CD80—multiple sclerosis	5.75e-06	5.76e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TYK2—multiple sclerosis	5.75e-06	5.76e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—POMC—multiple sclerosis	5.73e-06	5.74e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—ICAM1—multiple sclerosis	5.72e-06	5.73e-05	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—MAPK1—multiple sclerosis	5.64e-06	5.66e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—APOE—multiple sclerosis	5.62e-06	5.64e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CCL2—multiple sclerosis	5.6e-06	5.62e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—BCHE—multiple sclerosis	5.59e-06	5.6e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CXCL10—multiple sclerosis	5.58e-06	5.59e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—TGFB1—multiple sclerosis	5.57e-06	5.58e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—TGFB1—multiple sclerosis	5.57e-06	5.58e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—POMC—multiple sclerosis	5.54e-06	5.55e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—POMC—multiple sclerosis	5.54e-06	5.55e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—ICAM1—multiple sclerosis	5.54e-06	5.55e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—ICAM1—multiple sclerosis	5.54e-06	5.55e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD80—multiple sclerosis	5.51e-06	5.52e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—POMC—multiple sclerosis	5.47e-06	5.48e-05	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—MAPK1—multiple sclerosis	5.46e-06	5.47e-05	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—MAPK1—multiple sclerosis	5.46e-06	5.47e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL2—multiple sclerosis	5.45e-06	5.46e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—APOE—multiple sclerosis	5.44e-06	5.45e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—APOE—multiple sclerosis	5.44e-06	5.45e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—IL6—multiple sclerosis	5.43e-06	5.44e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CCL2—multiple sclerosis	5.42e-06	5.43e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CCL2—multiple sclerosis	5.42e-06	5.43e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CXCL10—multiple sclerosis	5.4e-06	5.41e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CXCL10—multiple sclerosis	5.4e-06	5.41e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CCL2—multiple sclerosis	5.35e-06	5.36e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD80—multiple sclerosis	5.33e-06	5.34e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD80—multiple sclerosis	5.33e-06	5.34e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—MAPK1—multiple sclerosis	5.23e-06	5.24e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MMP9—multiple sclerosis	5.16e-06	5.17e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—TYK2—multiple sclerosis	5.09e-06	5.1e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CD80—multiple sclerosis	5.09e-06	5.1e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—MAPK1—multiple sclerosis	5.08e-06	5.09e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—TYK2—multiple sclerosis	4.92e-06	4.93e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—TYK2—multiple sclerosis	4.92e-06	4.93e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CD80—multiple sclerosis	4.92e-06	4.93e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CD80—multiple sclerosis	4.92e-06	4.93e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—MAPK1—multiple sclerosis	4.92e-06	4.93e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—MAPK1—multiple sclerosis	4.92e-06	4.93e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CD86—multiple sclerosis	4.88e-06	4.89e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TYK2—multiple sclerosis	4.86e-06	4.87e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—APOE—multiple sclerosis	4.84e-06	4.85e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCL5—multiple sclerosis	4.81e-06	4.82e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL2—multiple sclerosis	4.78e-06	4.79e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—IL6—multiple sclerosis	4.76e-06	4.77e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CD86—multiple sclerosis	4.72e-06	4.73e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CD86—multiple sclerosis	4.72e-06	4.73e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—APOE—multiple sclerosis	4.71e-06	4.72e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—TYK2—multiple sclerosis	4.65e-06	4.66e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCL5—multiple sclerosis	4.65e-06	4.66e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCL5—multiple sclerosis	4.65e-06	4.66e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—STAT3—multiple sclerosis	4.59e-06	4.6e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—APOE—multiple sclerosis	4.56e-06	4.57e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—APOE—multiple sclerosis	4.56e-06	4.57e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MMP9—multiple sclerosis	4.53e-06	4.53e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—TYK2—multiple sclerosis	4.5e-06	4.51e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—TYK2—multiple sclerosis	4.5e-06	4.51e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—SPP1—multiple sclerosis	4.45e-06	4.46e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IFNG—multiple sclerosis	4.35e-06	4.36e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCR5—multiple sclerosis	4.33e-06	4.34e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—SPP1—multiple sclerosis	4.31e-06	4.31e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—SPP1—multiple sclerosis	4.31e-06	4.31e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—TYK2—multiple sclerosis	4.29e-06	4.3e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL2RA—multiple sclerosis	4.27e-06	4.28e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MYC—multiple sclerosis	4.26e-06	4.27e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—TGFB1—multiple sclerosis	4.25e-06	4.26e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL2—multiple sclerosis	4.23e-06	4.24e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IFNG—multiple sclerosis	4.21e-06	4.22e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IFNG—multiple sclerosis	4.21e-06	4.22e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD4—multiple sclerosis	4.2e-06	4.21e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCR5—multiple sclerosis	4.19e-06	4.2e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCR5—multiple sclerosis	4.19e-06	4.2e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—MAPK1—multiple sclerosis	4.17e-06	4.18e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—POMC—multiple sclerosis	4.16e-06	4.17e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—TYK2—multiple sclerosis	4.15e-06	4.16e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—TYK2—multiple sclerosis	4.15e-06	4.16e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL2RA—multiple sclerosis	4.13e-06	4.14e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL2RA—multiple sclerosis	4.13e-06	4.14e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—APOE—multiple sclerosis	4.1e-06	4.11e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL2—multiple sclerosis	4.1e-06	4.1e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL2—multiple sclerosis	4.1e-06	4.1e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD4—multiple sclerosis	4.07e-06	4.08e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD4—multiple sclerosis	4.07e-06	4.08e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—POMC—multiple sclerosis	4.05e-06	4.05e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL2—multiple sclerosis	4.04e-06	4.05e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—STAT3—multiple sclerosis	4.02e-06	4.03e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—IL6—multiple sclerosis	4.02e-06	4.03e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—APOE—multiple sclerosis	3.94e-06	3.95e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—POMC—multiple sclerosis	3.91e-06	3.92e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—POMC—multiple sclerosis	3.91e-06	3.92e-05	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—IL6—multiple sclerosis	3.9e-06	3.91e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL1B—multiple sclerosis	3.88e-06	3.89e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—CD4—multiple sclerosis	3.88e-06	3.89e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL2—multiple sclerosis	3.87e-06	3.88e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MMP9—multiple sclerosis	3.82e-06	3.83e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—APOE—multiple sclerosis	3.81e-06	3.82e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—APOE—multiple sclerosis	3.81e-06	3.82e-05	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—ALB—multiple sclerosis	3.79e-06	3.8e-05	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—IL6—multiple sclerosis	3.78e-06	3.78e-05	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—IL6—multiple sclerosis	3.78e-06	3.78e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL1B—multiple sclerosis	3.76e-06	3.76e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL1B—multiple sclerosis	3.76e-06	3.76e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—CD4—multiple sclerosis	3.76e-06	3.76e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—CD4—multiple sclerosis	3.76e-06	3.76e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL2—multiple sclerosis	3.74e-06	3.75e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL2—multiple sclerosis	3.74e-06	3.75e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MYC—multiple sclerosis	3.74e-06	3.75e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—TGFB1—multiple sclerosis	3.73e-06	3.74e-05	CbGpPWpGaD
Loperamide—CALM3—Metabolism—ALB—multiple sclerosis	3.69e-06	3.7e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—MAPK1—multiple sclerosis	3.66e-06	3.66e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—BCHE—multiple sclerosis	3.66e-06	3.66e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—APOE—multiple sclerosis	3.57e-06	3.58e-05	CbGpPWpGaD
Loperamide—CALM2—Metabolism—ALB—multiple sclerosis	3.57e-06	3.58e-05	CbGpPWpGaD
Loperamide—CALM1—Metabolism—ALB—multiple sclerosis	3.57e-06	3.58e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CD80—multiple sclerosis	3.56e-06	3.57e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—POMC—multiple sclerosis	3.52e-06	3.53e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CD80—multiple sclerosis	3.44e-06	3.45e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CD80—multiple sclerosis	3.44e-06	3.45e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—STAT3—multiple sclerosis	3.4e-06	3.41e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—POMC—multiple sclerosis	3.38e-06	3.39e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—APOE—multiple sclerosis	3.36e-06	3.37e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCL2—multiple sclerosis	3.31e-06	3.32e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—POMC—multiple sclerosis	3.27e-06	3.28e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—POMC—multiple sclerosis	3.27e-06	3.28e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—STAT3—multiple sclerosis	3.26e-06	3.26e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—MAPK1—multiple sclerosis	3.24e-06	3.25e-05	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ALB—multiple sclerosis	3.21e-06	3.22e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL6—multiple sclerosis	3.21e-06	3.21e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCL2—multiple sclerosis	3.2e-06	3.21e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCL2—multiple sclerosis	3.2e-06	3.21e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MYC—multiple sclerosis	3.16e-06	3.17e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—TGFB1—multiple sclerosis	3.15e-06	3.16e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—STAT3—multiple sclerosis	3.15e-06	3.16e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—STAT3—multiple sclerosis	3.15e-06	3.16e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—MAPK1—multiple sclerosis	3.13e-06	3.14e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—MAPK1—multiple sclerosis	3.13e-06	3.14e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—MAPK1—multiple sclerosis	3.09e-06	3.1e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—POMC—multiple sclerosis	3.07e-06	3.07e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TYK2—multiple sclerosis	3.01e-06	3.01e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—STAT3—multiple sclerosis	3.01e-06	3.01e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—MAPK1—multiple sclerosis	2.96e-06	2.97e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TYK2—multiple sclerosis	2.91e-06	2.91e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TYK2—multiple sclerosis	2.91e-06	2.91e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—STAT3—multiple sclerosis	2.91e-06	2.91e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—STAT3—multiple sclerosis	2.91e-06	2.91e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—POMC—multiple sclerosis	2.89e-06	2.9e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—MAPK1—multiple sclerosis	2.86e-06	2.87e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—MAPK1—multiple sclerosis	2.86e-06	2.87e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL6—multiple sclerosis	2.81e-06	2.82e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ALB—multiple sclerosis	2.8e-06	2.8e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MYC—multiple sclerosis	2.79e-06	2.8e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—TGFB1—multiple sclerosis	2.79e-06	2.79e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—MAPK1—multiple sclerosis	2.73e-06	2.74e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MYC—multiple sclerosis	2.7e-06	2.71e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MYC—multiple sclerosis	2.7e-06	2.71e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—TGFB1—multiple sclerosis	2.7e-06	2.7e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—TGFB1—multiple sclerosis	2.7e-06	2.7e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—MAPK1—multiple sclerosis	2.64e-06	2.65e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—MAPK1—multiple sclerosis	2.64e-06	2.65e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ALB—multiple sclerosis	2.63e-06	2.64e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL2—multiple sclerosis	2.5e-06	2.51e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL6—multiple sclerosis	2.49e-06	2.49e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL2—multiple sclerosis	2.42e-06	2.42e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL2—multiple sclerosis	2.42e-06	2.42e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL6—multiple sclerosis	2.41e-06	2.41e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL6—multiple sclerosis	2.41e-06	2.41e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL6—multiple sclerosis	2.38e-06	2.38e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MMP9—multiple sclerosis	2.37e-06	2.37e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MMP9—multiple sclerosis	2.29e-06	2.29e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MMP9—multiple sclerosis	2.29e-06	2.29e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL6—multiple sclerosis	2.27e-06	2.28e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL6—multiple sclerosis	2.2e-06	2.2e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL6—multiple sclerosis	2.2e-06	2.2e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—APOE—multiple sclerosis	2.2e-06	2.2e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—STAT3—multiple sclerosis	2.1e-06	2.11e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—IL6—multiple sclerosis	2.1e-06	2.1e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—STAT3—multiple sclerosis	2.04e-06	2.04e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—STAT3—multiple sclerosis	2.04e-06	2.04e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—IL6—multiple sclerosis	2.03e-06	2.04e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—IL6—multiple sclerosis	2.03e-06	2.04e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MYC—multiple sclerosis	1.96e-06	1.96e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—TGFB1—multiple sclerosis	1.95e-06	1.96e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—MAPK1—multiple sclerosis	1.91e-06	1.92e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MYC—multiple sclerosis	1.89e-06	1.9e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MYC—multiple sclerosis	1.89e-06	1.9e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—POMC—multiple sclerosis	1.89e-06	1.89e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—TGFB1—multiple sclerosis	1.89e-06	1.89e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—TGFB1—multiple sclerosis	1.89e-06	1.89e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—MAPK1—multiple sclerosis	1.85e-06	1.85e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—MAPK1—multiple sclerosis	1.85e-06	1.85e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ALB—multiple sclerosis	1.72e-06	1.73e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL6—multiple sclerosis	1.47e-06	1.47e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL6—multiple sclerosis	1.42e-06	1.43e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL6—multiple sclerosis	1.42e-06	1.43e-05	CbGpPWpGaD
